University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
A special concert to say thank you and pay tribute to the achievements of the Oxford vaccine team has been recorded at the Sheldonian Theatre for a film screening in time for Christmas
The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University\u2019s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
First results of the What\u2019s the STORY (Serum Testing Of Representative Youngsters) trial indicate higher resilience of children to COVID-19 compared to other respiratory illnesses.
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
The Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
Bristol Science Film Festival awarded the Professional Science Fact Film Prize to \"The Adventures of Alice in Typhoidland\" co-created by the Oxford Vaccine Group.
The Government has announced \u00a365.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate.
![\"None\"](\"https://www.ovg.ox.ac.uk/news/first-peer-reviewed-results-of-phase-3-human-trials-of-oxford-coronavirus-vaccine-demonstrate-efficacy/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n